Aidapak Recalls Nefazodone 200 mg Tablets Due to Labeling Error
Aidapak Services, LLC is recalling Nefazodone HCL 200 mg tablets because they may have been mislabeled as 150 mg tablets.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II and involves a labeling error (label mixup) without reported injuries or illnesses, fitting the criteria for a moderate severity score.
Plain-English summary
Aidapak Services, LLC is recalling Nefazodone HCL, Tablet, 200 mg (NDC 00093102506) due to a labeling error. The recalled product may have been mislabeled as Nefazodone HCL, Tablet, 150 mg (NDC 00093711306). The affected product has the pedigree AD46414_44 and an expiration date of 5/16/2014.
The repacked drugs were distributed in Arizona, California, Oregon, and Washington. The FDA has classified this recall as Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
Consumers who have this product should contact their pharmacist or healthcare provider for instructions on how to dispose of the medication or obtain a replacement.
The recalled product
- Product
- NEFAZODONE HCL, Tablet, 200 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093102506.
- Manufacturer
- Aidapak Services, LLC
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 60
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- NEFAZODONE HCL
- Tablet
- 200 mg has the following codes: Pedigree: AD46414_44
- EXP: 5/16/2014
Distribution
Part of a larger recall action
This product is one of 265 recalled by Aidapak Services, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 265 products in this recall →Related recalls
Same manufacturer · Aidapak Services, LLC
See all →- ModerateAidapak Recalls Sennosides Tablets Due to Potential Labeling Errors
FDA (Drugs) · 2014-01-29
- ModerateLevothyroxine Sodium Tablets Recalled for Potential Labeling Mixup
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Mislabeled Pantoprazole Sodium DR Tablets
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Nifedipine ER Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-29
- ModerateSimvastatin Tablets Recalled for Potential Labeling Error
FDA (Drugs) · 2014-01-29
Same hazard · mis labeling
See all →- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-10-14
- SevereBetter Bakehouse Recalls Donutful Chocolate Dipped Vanilla Cake Donuts for Undeclared Milk
FDA (Food) · 2026-10-14
- HighFreshPoint Recalls Cranberry Chicken Salad Wedges for Undeclared Egg Allergen
FDA (Food) · 2026-10-14
- HighJ K Patisserie & Bakery LLC Recalls Croissants for Undeclared Egg
FDA (Food) · 2026-10-14
- LowMindray ePM Series Patient Monitor Manuals Recalled for Alarm Clarification
FDA (Devices) · 2026-10-14
Similar recalls
- ModerateAidapak Recalls Benazepril HCL Tablets Due to Potential Labeling Errors
FDA (Drugs) · 2014-01-22
- SevereFDA Recalls FIDAXOMICIN Tablets Due to Potential Labeling Error
FDA (Drugs) · 2014-01-22
- SevereAidapak Recalls OXcarbazepine Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-22
- SevereAidapak Recalls Trazodone Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-22
- SevereRivaroxaban Tablets Recalled for Potential Venlafaxine Labeling Error
FDA (Drugs) · 2014-01-22
- ModerateAidapak Recalls Benazepril HCL Tablets Due to Potential Labeling Error
FDA (Drugs) · 2014-01-22